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(57) ABSTRACT 
A method for preparing a stable dispersion of a camptothecin, 
camptothecin prodrug, or analog thereof for administration to 
a patient in need thereof includes preparing a solution of the 
camptothecin, Wherein the solution has a pH Which places 
substantially an entirety of that camptothecin in a carboxylate 
form. The camptothecin may be a neutral camptothecin. The 
solution is next loaded into a liposome including at least one 
lipid, Which may be a phospholipid. An intraliposomal pH is 
maintained Which preserves substantially an entirety of the 
camptothecin in the carboxylate form. The liposomal disper 
sion is administered to an individual in need thereof, Whereby 
the liposomes accumulate at and permeate into tumor tissue 
and an active, lactone form camptothecin is released in situ at 
the tumor site. Compositions formulated in accordance With 
the described method for treatment of a cancer in an animal in 
need thereof are provided also. 
24 Claims, 3 Drawing Sheets 
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LIPOSOMAL, RING-OPENED 
CAMPTOTHECINS WITH PROLONGED, 
SITE-SPECIFIC DELIVERY OF ACTIVE 
DRUG TO SOLID TUMORS 
This invention Was made With Government support under 
NIH/N CI Grant R0l-CA-8706l. The Government may have 
certain rights in this invention. 
TECHNICAL FIELD 
The present invention relates to the ?eld of compositions 
for treatment of a cancer in an animal, and to methods for 
preparing such compositions. In particular, the present inven 
tion relates to a method for formulating a stable liposomal 
camptothecin or analog thereof, and to compositions formu 
lated thereby. 
BACKGROUND OF THE INVENTION 
Structure-activity studies shoW that successful inhibition 
of DNA topoisomerase I by camptothecin analogues requires 
an intact lactone ring (E-ring) functionality. Camptothecin 
analogs having open lactone ring structures (also knoWn as 
the carboxylate form or as camptothecin carboxylates) are 
poorly accumulated by cancer cells, exhibit limited activity 
against the topoisomerase enzyme, and may be more toxic to 
healthy cells than the lactone form. 
Unfortunately, in aqueous solutions, camptothecins 
undergo a pH dependent hydrolysis to the inactive carboxy 
late form (FIG. 1). This, coupled With the fact that the inactive 
carboxylate form is favored in aqueous solution at pH 7.4 may 
account for the limited clinical success of certain camptoth 
ecins. Even more, under physiological conditions such as in 
blood, this equilibrium may shift further toWard the inactive 
carboxylate form by preferential carboxylate binding to 
serum albumin, Which affects certain congeners more than 
others. 
Camptothecins may be further subclassi?ed into neutral 
and cationic camptothecins. Camptothecins Which exist pri 
marily as neutral species at pH less than 7 are generally 
classi?ed as neutral, Whereas camptothecins having cationic 
substituent groups in the parent structure and Which exist 
predominantly as positively charged species at pH less than 7 
are classi?ed as cationic camptothecins. Both subspecies of 
camptothecins undergo chemical degradation by lactone ring 
hydrolysis to the inactive carboxylate form as described 
above. It is knoWn that neutral camptothecins are signi?cantly 
less Water-soluble at loW pH than their cationic counterparts. 
This poor Water-solubility has severely limited the types of 
formulations and drug concentrations of highly lipophilic 
neutral camptothecinsm, prodrugs and analogs [e.g., l0-hy 
droxy-7-ethyl camptothecin (SN38), silatecan 7-t-butyldim 
ethylsilyl-l0-hydroxycamptothecin (DB-67), karenitecan, 
gimatecan, irinotecan, 9-nitro camptothecin, and the like] that 
can be employed for clinical treatment of cancer, even though 
lipophilic camptothecins and analogs provide several impor 
tant advantages over their Water-soluble counterparts. For 
example, because of its increased lipophilicity and dual 
7-alkylsilyl and l0-hydroxy substitution, DB-67 displays 
superior binding to cellular and liposomal membranes and 
enhanced drug stability in the presence of human serum albu 
min When compared With clinically relevant, more hydro 
philic camptothecin analogues. Indeed, in vitro cytotoxicity 
assays indicate that DB-67 has at least comparable potency 
With other FDA approved camptothecin analogs (e.g., Camp 
tosar and Hycamtin). 
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It is knoWn to utilize liposomes as delivery vehicles for 
camptothecins. Liposomal encapsulation can improve solu 
bility of both neutral and cationic camptothecins, overcoming 
knoWn Water insolubility of camptothecins and analogs and 
also minimizing side effects of camptothecins relating to their 
cytotoxicity by more closely targeting delivery to tumor tis 
sue. In addition, it has been shoWn that liposomes may accu 
mulate in tumor tissue after delivery due to an enhanced 
permeation and retention effect ((Drummond, D. C., Meyer, 
O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. 1999, 
Optimizing liposomes for delivery of chemotherapeutic 
agents to solid tumors, Pharmacol. Rev. 51(4): 691-743)), 
providing a more targeted drug delivery and enabling passive 
tumor targeting. That is, drug encapsulation in liposomes can 
improve drug distribution (preferentially to tumor tissue 
rather than normal tissue) by reducing drug access to normal 
tissue. Speci?cally, the enhanced permeability of the 
microvasculature in tumor tissue alloWs particles having the 
size range of a liposome to escape from the blood circulature 
and collect in tumor tissue. Once in the tumor bed, particles 
such as liposomes are retained in tumor tissue for an increased 
period of time. 
Camptothecins in the active lactone form partition prefer 
entially into liposomal membranes, thus minimizing expo 
sure to the aqueous environment and decreasing unWanted 
conversion of the active lactone form to the inactive carboxy 
late form. For this reason, typically a loW intraliposomal pH is 
maintained to stabilize camptothecins held therein in the 
active lactone form. This formulation strategy typically 
requires use of an aqueous buffer and, While effective for 
cationic camptothecins, is unsuitable for neutral camptoth 
ecins due to their reduced Water-solubility at loW pH as noted 
above. Accordingly, While liposomal delivery technology is 
an effective method of delivery for camptothecins, presently 
it is less suited to delivery of neutral camptothecins due to the 
di?iculties in achieving adequate concentrations of liposome 
bound drug, and also to inadequate retention of the lactone 
form of the drug in liposomes after injection. Indeed, inad 
equate retention of lactone-form neutral camptothecins in 
liposomes after delivery to patients limits or eliminates any 
advantage provided by liposomal delivery compared to con 
ventional dosage forms such as injectable solutions. 
Especially for the advantages provided by use of neutral 
camptothecins compared to cationic camptothecins, that is, 
enhanced membrane-binding and superior drug stability in 
the presence of blood components such as albumin, there 
remains a need in the art for pharmaceutical formulations 
comprising neutral camptothecins for treatment of various 
cancers. Such formulations should provide a stable camptoth 
ecin formulation, and also improve retention of intraliposo 
mal drug, promoting passive targeting of tumor tissue by 
liposomes and delivery of increased dosages of drug to such 
tumor tissue While reducing effects on healthy tissue. 
SUMMARY OF THE INVENTION 
In accordance With the foregoing identi?ed need, a novel 
method for preparing a liposomal formulation of a camptoth 
ecin, prodrug, or analog thereof, and compositions formu 
lated thereby, are provided. In one aspect, a method is pro 
vided for preparing a stable dispersion of a camptothecin, 
prodrug, or analog thereof for delivery to a patient in need 
thereof. The method includes preparing a solution of a camp 
tothecin, prodrug, or analog thereof, Wherein the solution has 
a pH Which places substantially an entirety of that camptoth 
ecin, prodrug, or analo g thereof in substantially a ring-opened 
carboxylate form. Next, the solution is loaded into a liposome 
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having an intraliposomal pH Which preserves substantially an 
entirety of the intraliposomal camptothecin, prodrug, or ana 
log thereof in the ring-opened, carboxylate form. Next is the 
step of delivering the liposome to a patient in need thereof, 
Whereby the liposome accumulates at a tumor site and the 
camptothecin, prodrug or analog thereof is released as an 
active, lactone form in situ at the tumor site. 
The solution of camptothecin, prodrug, or analog thereof 
may be formulated to have a pH of from about 9.0 to about 
11.0. In one aspect of the invention, a neutral camptothecin, 
prodrug, or analog thereof is utiliZed, including Without limi 
tation camptothecin, DB-67, SN-38, gimatecan, karenitecin, 
irinotecan, 9-nitro camptothecin, and mixtures thereof. 
The liposome Will typically be formulated to include at 
least one lipid, typically selected from at least one of a phos 
pholipid and/or a sterol, for example cholesterol. The lipo 
some may further include a sphingolipid. That phospholipid 
may be a synthetic or a natural phospholipid, and may be an 
egg phospholipid, a soy phospholipid, distearoylphosphati 
dyl choline, dipalmitoylphosphatidyl choline, diarachi 
donoyl phosphatidyl choline, hydrogenated soy phosphatidyl 
choline, dimyristoylphosphatidyl glycerol, dioleylphosphati 
dylglycerol, dimyristoylphosphatidylcholine, phosphatidyl 
choline, pho sphatidyl ethanolamine, and any mixture thereof. 
Optionally, the liposome may be prepared from a mixture of 
phospholipids including from about 5% to about 10% of a 
pegylated phospholipid. In one embodiment, the liposome 
may include from about 70% to about 95% (W/v) of a ?rst 
phospholipid and from about 5% to about 10% (W/v) of a 
second, pegylated phospholipid. The chain length of the ?rst 
phospholipid may be selected to be substantially the same as 
the chain length of the second, pegylated phospholipid. 
In another aspect, a method is provided for administering a 
stable dispersion comprising a neutral camptothecin or ana 
log thereof to an animal, including a human, in need thereof. 
The method is substantially as described above, With the 
further step of separating liposomes containing entrapped 
neutral camptothecins, prodrugs, or analogs thereof from any 
free drug before administering the liposome preparation. The 
liposome is then delivered to a patient in need thereof, 
Whereby the liposome accumulates at a tumor site and the 
neutral camptothecin, prodrug, or analog thereof is released 
as an active, lactone form in situ at the tumor site. 
In yet another aspect, a composition providing a therapeu 
tically su?icient amount of a camptothecin, prodrug, or ana 
log thereof, Which may be a neutral camptothecin, for the 
treatment of a cancer in an animal, including a human, in need 
thereof is provided. The camptothecin, prodrug, or analog 
thereof is loaded into a liposome having an intraliposomal pH 
suf?cient to maintain substantially an entirety of the intrali 
posomal neutral camptothecin, prodrug, or analog thereof in 
a carboxylate form. The methods for loading the camptoth 
ecin, prodrug, or analog into the liposome and the lipids and 
drugs suitable for preparing the composition, are substan 
tially as described above. The composition may be formu 
lated for delivery to a patient in need thereof, such as in an 
injectable formulation. Upon such delivery, the liposome 
comprising entrapped drug accumulates at and permeates 
into a tumor site. Over time, the camptothecin, prodrug or 
analog thereof is released as an active, lactone form in situ at 
the tumor site. 
Other objects and applications of the present invention Will 
become apparent to those skilled in this art from the folloWing 
description Wherein there is shoWn and described a preferred 
embodiment of this invention, simply by Way of illustration of 
the modes currently best suited to carry out the invention. As 
it Will be realiZed, the invention is capable of other different 
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embodiments and its several details are capable of modi?ca 
tion in various, obvious aspects all Without departing from the 
invention. Accordingly, the draWings and descriptions Will be 
regarded as illustrative in nature and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWING 
The accompanying draWing incorporated in and forming a 
part of the speci?cation illustrates several aspects of the 
present invention and, together With the description, serves to 
explain the principles of the invention. In the draWing: 
FIG. 1 depicts the reversible lactone ring-opening reaction 
in camptothecins; 
FIG. 2 shoWs liposomal release of DB-67 in aqueous solu 
tion at pH 4 vs. pH 9.5; and 
FIG. 3 shoWs liposomal release of DB-67 in plasma at pH 
4.5 vs. pH 9.5. 
Reference Will noW be made in detail to the presently 
preferred embodiments, examples of Which are illustrated in 
the accompanying draWing. 
DETAILED DESCRIPTION OF THE INVENTION 
As summarized above, described herein are novel methods 
for providing liposomal formulations of camptothecins, 
camptothecin prodrugs, and analogs thereof, and composi 
tions formulated thereby. It Will be understood that the term 
camptothecin as used herein is intended to refer collectively 
to various camptothecins, camptothecin prodrugs, and camp 
tothecin analogs as are Well knoWn in the art. The methods 
and compositions described herein may be accomplished by 
various means Which are illustrated in the examples beloW. 
These examples are intended to be illustrative only, as numer 
ous modi?cations and variations Will be apparent to those 
skilled in the art. 
It is knoWn that at pH ranges Which favor the lactone-form 
camptothecin, during liposomal encapsulation the drug pref 
erentially partitions into liposomal membranes. This mini 
miZes exposure to the aqueous environment, resulting in a 
decrease in ring opening of the active lactone. Accordingly, 
conventional liposomal formulations for camptothecins 
employ a loW pH in liposomes to stabiliZe camptothecins in 
the active lactone form. HoWever, this strategy requires use of 
an aqueous buffer to dissolve the drug prior to preparation of 
liposomes by conventional hydration-extrusion, sonication, 
or drug-lipid ?lm techniques. Because of the loW Water-solu 
bility of neutral camptothecins and the concomitant reduc 
tions in retention time for liposomal formulations of neutral 
camptothecins (see Table 1), such conventional strategies are 
more favorable to liposomal encapsulation of cationic camp 
tothecins than neutral camptothecins. 
TABLE 1 
Percent retention vs. circulation time for investigational 
liposomal camptothecins 
% retention 
Camptothecin Status 4 hr 24 hr 
Lultotecanl Phase 11 ~50 <0.1 
Topotecan2 Preclinical 23 ~0 
Irinotecan3 Preclinical 68* 8* 
US 8,067,432 B2 
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TABLE l-continued 
Percent retention vs. circulation time for investigational 
liposomal carnptothecins 
% retention 
Carnptothecin Status 4 hr 24 hr 
DB-674 Preclinical <1 ND 
SN-3 85 Phase r/n <1 <0.1 
lEmerson et al., 2000, Antitumor e?icacy, pharmacokinetics, and biodistribution of 
N'X-211: A low-clearance liposomal formulation of lurtotecan. Clin. Canc. Res. 6: 2903 
2912; Colbern et al., 1998, Encapsulation of the topoisomerase I inhibitor GL147211C in 
pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon 
tumor xenogra?s, Clin. Canc. Res. 4: 3077-3082. 
2Tardi et al., 2000, Liposomal encapsulation oftopotecan enhances anticancer e?icacy in 
murine and human xenogIaft models. Cancer Res. 60: 3389-3393. 
3Messerer et al., 2004, Liposomal irinotecan: formulation development and therapeutic 
assessment in murine xenogra? models of colorectal cancer, Clin. Canc. Res. 10: 6638 
6649. 
4Zamboni et al., 2005, Plasma and tissue disposition ofnon-liposomal DB-67 and liposomal 
DB-67 in CB-17 SCID mice. Investigational New Drugs, published on-line February 2008 
(DOI10.1007/s10637-007-9109-9). Pal et al., 2005, Preclinical safety, pharmacokinetics and antitumor e?icacy pro?le of 
liposome-entrapped SN-38 formulation, Anticancer Res. 25: 331-341. 
Camptothecins, including neutral camptothecins, exist 
predominantly in the active lactone form in aqueous solution 
at pH less than 6.0, whereas the inactive carboxylate species 
dominates in aqueous solution at pH above 6.0. At physi 
ological pH (7.4), approximately 70% of camptothecin is in 
the carboxylate form. Thus, in plasma, approximately 70% of 
the drug is in carboxylate (inactive) form and 30% in lactone 
(active) form. The half-life of lactone-form camptothecin in 
rat plasma is approximately 40 min. Encapsulating the lac 
tone form of a representative neutral camptothecin, DB-67, in 
pegylated liposomes at low pH (4) prolongs the half-life of 
the drug. However, at this pH it was not possible to retain the 
drug in liposomes in aqueous buffers for long periods of time. 
It has been found that preparing liposomes containing 
entrapped camptothecins, prodrugs, or analogs thereof, 
including neutral camptothecins, at a pH su?icient to keep 
substantially an entirety of the intraliposomal drug in the 
inactive carboxylate form signi?cantly increased the half-life 
for retention in liposomes. This is because the release of the 
carboxylate form from the liposomes is negligible. Surpris 
ingly, however, slow conversion of the entrapped, ring 
opened carboxylate occurs, providing a low, steady-state con 
centration of lactone form drug which is then slowly released 
from the liposome. Thus, the present invention provides a 
slow and prolonged release of the active lactone form from 
the liposome. This release rate can be varied by changing the 
intraliposomal pH. That is, an increase in the intraliposomal 
pH slows the release of active lactone from the liposome, and 
vice-versa. 
The compositions contemplated herein may be formulated 
for delivery to patients in need thereof using methods and 
formulations well within the skill in the art. For example, the 
compositions may be prepared for direct delivery, or as phar 
maceutical formulations along with suitable carriers or 
excipients as are well known to the skilled artisan. For 
example, one or more additives may be included with the 
compositions, such as one or more stabilizers, buffers, salts, 
preservatives, ?llers, and the like. Suitable buffers include 
without limitation phosphates, carbonates, citrates, and oth 
ers. Suitable preservatives include without limitation EDTA, 
EGTA, BHA, BHT, and others. 
The skilled artisan will also readily appreciate that phar 
maceutical formulations comprising the present composi 
tions will be highly dependent on the route of administration 
chosen. By way of non-limiting example, injectable formu 
lations of the compositions may be provided as aqueous solu 
tions, typically in physiologically compatible buffers such as 
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Hank’s solution, Ringer’s solution, or physiological saline 
buffer. Pharmaceutical formulations intended for parenteral 
injection, e.g., by bolus injection or continuous infusion, may 
be provided in unit dosage form, e.g., in ampoules or in 
multi-do se containers, typically with an added preservative as 
set forth above. 
EXAMPLES 
Set forth in greater detail below are speci?c details related 
to selected modes for carrying out the methods and compo 
sitions of the present invention. The examples set forth herein 
are in no way intended to limit the scope of the invention. 
Those of skill in the art will realiZe that, given the teachings 
provided herein, many variations of the methods are possible 
that will fall within the scope of the present invention. Unless 
otherwise indicated, all citations of literature are speci?cally 
incorporated by reference herein in their entirety. 
Example 1 
Phospholipids and pegylated phospholipids were pur 
chased as powders fromAvanti Polar Lipids (Alabaster, Ala.). 
A representative neutral camptothecin, DB-67, was from 
Novartis Pharmaceutical Corp. (East Hanover, N.J.). Spra 
gue-Dawley rat plasma was from Bioreclamation, Inc. (East 
Meadow, N.Y.). CENTRICON® (MWCO: 100000) centrifu 
gal ?lter devices from Millipore (Billerica, Mass.) and 
SEPHADEX® G-25 M prepacked siZe exclusion columns 
(GE Healicare Bio-sciences Corp., Piscataway, NJ.) were 
used in liposome studies. All other reagents were from Fisher 
Scienti?c (Florence, Ky). 
Liposomes were prepared by conventional hydration-ex 
trusion technique. However, the skilled artisan will appreciate 
that any suitable method for preparing liposomes having a 
desired particle siZe and lamellarity is contemplated. In one 
aspect, liposomes having a particle siZe range of from about 
50 to about 300 nm are contemplated for use in the present 
invention. Methods for preparing liposomes falling within a 
predetermined siZe range are known in the art (see Drum 
mond et al., 1999). 
For the hydration-extrusion technique, ?lms of the desired 
lipid mixtures were prepared in test tubes by dissolving 
weighed amounts of lipids in chloroform, evaporating the 
solvent under nitrogen, and drying overnight in vacuo. A 
stock solution of drug (DB-67) in a buffer providing the 
desired pH was added to hydrate the lipids, followed by 
shaking and extrusion through polycarbonate membranes at 
600 C. to obtain unilamellar vesicles containing entrapped 
drug. Thus, intraliposomal pH of the ?nal liposome-en 
trapped drug preparation prepared as described was substan 
tially in accordance with the pH of the buffer/DB-67 solution 
in which phospholipid mixtures were hydrated. 
Example 2 
The liposomal permeability of DB-67 in aqueous solution 
was measured over a pH range of 4.5 to 9.5 using a dynamic 
dialysis method [V. Joguparthi and B. D. Anderson, Liposo 
mal delivery of hydrophobic weak acids: Enhancement of 
drug retention using a high intraliposomal pH, J. Pharm. Sci. 
97, 433-454 (2008)]. Liposome-encapsulated DB-67 solu 
tions were prepared at varying pH values as described above. 
For liposome solutions at each pH evaluated, liposome-en 
trapped drug was separated from free drug by passing lipo 
somes through a SEPHADEX® column followed by 5 mL of 
the same buffer added in 1 mL increments. The liposome 
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containing eluent Was dialyZed at 37° C. in the same buffer. At 
intervals, 100 pl of liposome suspension Was removed from 
the dialysis tube and added to 900 pl cold methanol/acetoni 
trile (2: 1, v/v). These samples Were dried under nitrogen and 
stored (—25° C.) prior to analysis. 
With reference to Table 2, DB-67 Was retained in lipo 
somes (prepared by hydration-extrusion) in aqueous solution 
for increased periods of time When liposomes Were prepared 
at high pH. In aqueous solution, the half-life for retention of 
DB-67 in liposomes increased from 3 hours at pH 4 to about 
90 hours at pH 9.5. Without being restricted to any particular 
theory, this may be due to conversion of DB-67 lactone to the 
carboxylate form in the intraliposomal space. 
TABLE 2 
Half-life for liposome retention of DB-67 at various pH. 
pH t1/2 (hours) 
4 3 
7.21 3.8 
7.78 5.4 
8.36 32.9 
8.95 57.9 
9.49 91.9 
As shoWn in FIG. 2, When intraliposomal pH Was main 
tained Whereby the carboxylate species of DB-67 predomi 
nated, release of the drug from liposomes Was negligible. For 
release to occur, pH conditions alloWing formation of the 
active, lactone species Were required. 
Example 3 
The e?iux of DB-67 from liposomes in plasma Was moni 
tored. Aliquots of liposome suspension containing DB-67 
(With unentrapped drug separated as described above) Were 
added to plasma and incubated at 37° C. At intervals, an 
aliquot of plasma Was WithdraWn, added to cold methanol/ 
acetonitrile (2:1 v/v), centrifuged (14000 rpm) and stored 
froZen (—25° C.) for HPLC analysis. 
HPLC analyses used herein have been previously 
described in detail (Joguparthi et al., 2006). DB-67 carboxy 
late standards (10-100 nM) Were prepared in 10 mM carbon 
ate buffer (pH 10.4). DB-67 lactone standards (5-30 nM) 
Were prepared in acidi?ed methanol. All standards Were 
diluted into the desired concentration range using cold metha 
nol/acetonitrile (2:1 v/v). HPLC retention times Were 1.6 and 
5.2 min for DB-67 carboxylate and lactone, respectively. 
FIG. 3 shoWs liposomal release of DB-67 in plasma at pH 
4.5 and pH 9.5. In plasma, the half-life for retention in lipo 
somes Was 3.5 hours When intraliposomal pH Was 4.5 and 6.3 
hours When intraliposomal pH Was 9.5. The half-life for 
retention at intraliposomal pH 9.5 Was less in plasma than in 
aqueous solution due to a decrease in intraliposomal pH 
observed after adding liposomes to plasma. HoWever, even in 
plasma, preparing liposomes at pH 9.5 and maintaining 
intraliposomal pH at levels Which preserve the carboxylate 
form of the entrapped neutral camptothecin prolonged intrali 
posomal retention. Thus, the potential for exposure of healthy 
tissue to the drug Was reduced. This improved intraliposomal 
retention enables the drug to remain in the liposomes While 
they are circulating in the bloodstream. After the liposomes 
collect in solid tumors due to their enhanced permeation 
across the tumor vasculature and their improved retention 
Within the tumor tissue (Drummond et al., 1999), the 
entrapped drug Will be sloWly released as the active, lactone 
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form of the drug directly at the tumor site, providing a sig 
ni?cant enhancement in ef?ciency of delivery. 
Example 4 
A 10 mg/ml solution of DB-67 Was prepared in pH 9.5 
sodium carbonate buffer and ?ltered through a 0.2 pm syringe 
?lter. The drug solution Was used to hydrate phospholipids 
(DSPC+5 mol % m-PEG DSPE) With shaking at 60° C. to 
form a 30 mg/ml suspension of multilamellar vesicles. The 
suspension Was extruded through a high pressure extruder to 
form unilamellar vesicles. The vesicles Were then cooled at 
room temperature and stored beloW 5° C. until use. Prior to 
use, liposomes Were separated from unentrapped DB-67 by 
passing through a gel ?ltration column Which Was pre-equili 
brated With pH 7.4 phosphate buffered saline. 100 pl of lipo 
somes collected from gel ?ltration Were immediately added 
to 4 ml of plasma to study the release of liposome-entrapped 
DB-67 carboxylate from plasma as described above. Samples 
Were taken at various time intervals and DB-67 Was extracted 
from 100 pl of plasma using 300 pl of ice-cold methanol 
solution and acetonitrile (2: 1 v/v) at —9° C. The concentration 
of DB-67 Was determined by HPLC as described above. 
Example 5 
A 10 mg/ml solution of DB-67 Was prepared in pH 9.5 
sodium carbonate buffer and ?ltered through a 0.2 pm syringe 
?lter. The drug solution Was used to hydrate phospholipids 
(DSPC+5 mol % m-PEG DSPE) With shaking at 60° C. to 
form a 30 mg/ml suspension of multilamellar vesicles. The 
suspension Was extruded through a high pressure extruder to 
form unilamellar vesicles. The vesicles Were then cooled at 
room temperature and stored beloW 5° C. until use. Prior to 
use, liposomes Were separated from unentrapped DB-67 by 
passing through a gel ?ltration column Which Was pre-equili 
brated With pH 9.5 sodium carbonate buffer. The liposomes 
collected from gel ?ltration Were immediately loaded into a 
dialysis tube and dialyZed (37 C) against 1000 ml of pH 9.5 
sodium carbonate buffer. DB-67 analysis Was by HPLC as 
described above. 
Example 6 
A 20 mg/ml solution of DB-67 is prepared in pH 10.5 
sodium carbonate buffer and ?ltered through a 0.2 pm syringe 
?lter. The drag solution is used to hydrate phospholipids 
(DSPC+5 mol % m-PEG DSPE) With shaking at 60° C. to 
form a 30 mg/ml suspension of multilamellar vesicles. The 
suspension is extruded through a high pressure extruder to 
form unilamellar vesicles. The vesicles are then cooled at 
room temperature and stored beloW 5° C. until use. Prior to 
use, liposomes are Warmed to room temperature and sepa 
rated from unentrapped DB-67 by gel ?ltration as described. 
Example 7 
10 mg of DB-67 is added to 60 mg of a phospholipid 
mixture in 2 ml of a 2:1 mixture of chloroform:ethanol. The 
solution is evaporated under nitrogen to form a drug-lipid 
?lm. The ?lm is hydrated With pH 10.5 carbonate buffer With 
shaking to form multilamellar vesicles. The suspension is 
extruded to form unilamellar vesicles. The vesicles are cooled 
to room temperature and unentrapped drug is separated from 
entrapped drug as described. The liposomes are then stored 
beloW 5° C. until use. 
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Example 8 
Drug is loaded in vesicles as described in Examples 6 and 
7, except the drug and phospholipids are dissolved in pure 
chloroform, pure acetone, pure methanol, or a suitable com 
bination of those solvents. Subsequently, solvent is evapo 
rated to form a drug-lipid ?lm. 
Example 9 
Unilamellar vesicles are prepared as described in 
Examples 4-8 using pH 9.5 borate buffer. 
Example 10 
Unilamellar vesicles are prepared as described in 
Examples 4-8 using pH 9.5 Tris-HCl buffer. 
Example 11 
Unilamellar vesicles are prepared as described in 
Examples 4-8 using pH 9.3 ammonium hydroxide. 
Example 12 
Unilamellar vesicles are prepared as described in 
Examples 4-8 using pH 9 glycine. 
Example 13 
Unilamellar vesicles are prepared as described in 
Examples 4-12, With the exception that the vesicles are 
formed by sonication rather than extrusion. 
Example 14 
Unilamellar vesicles are prepared as described in 
Examples 4-13, except the drug used is SN-38. 
Example 15 
Unilamellar vesicles are prepared as described in 
Examples 4-13, except the drug used is karenitecan. 
Example 16 
Unilamellar vesicles are prepared as described in 
Examples 4-13, except the drug used is gimatecan. 
Example 17 
Unilamellar vesicles are prepared as described in 
Examples 4-13, except the drug used is 9-nitro camptothecin. 
Example 18 
Unilamellar vesicles are prepared as described in 
Examples 4-17, With the exception that during separation of 
entrapped from unentrapped drug, the extraliposomal buffer 
is exchanged for pH 7.4 phosphate With the proviso that 
intraliposomal pH is maintained the same as that used in 
liposome preparation. 
Example 19 
Unilamellar vesicles are prepared as described in 
Examples 4-17, With the exception that during separation of 
entrapped from unentrapped drug, the extraliposomal buffer 
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is exchanged for a desired concentration of NaCl solution 
With the proviso that intraliposomal pH is maintained the 
same as that used in liposome preparation. 
Example 20 
Unilamellar vesicles are prepared as described in 
Examples 4-17, With the exception that during separation of 
entrapped from unentrapped drug, the extraliposomal buffer 
is exchanged for a desired concentration of sucrose solution, 
With the proviso that intraliposomal pH is maintained the 
same as that used in liposome preparation. 
Example 21 
Unilamellar vesicles are prepared as described in 
Examples 4-20, using a lipid mixture comprising 80% DSPC, 
15% cholesterol, and 5% m-PEG DSPE. 
Example 22 
Unilamellar vesicles are prepared as described in 
Examples 4-20, using a lipid mixture comprising 80% HSPC, 
15% cholesterol, and 5% pegylated PE. 
Example 23 
Unilamellar vesicles are prepared as described in 
Examples 4-20, using a lipid mixture comprising 55% DSPC, 
40% cholesterol, and 5% m-PEG DSPE. 
The skilled artisan Will readily appreciate that the present 
disclosure sets forth an ef?cient and ef?cacious method for 
preparing a liposomal formulation of a camptothecin, in one 
aspect being a neutral camptothecin, camptothecin prodrug, 
or analog thereof. Advantageously, the compositions formu 
lated by the present method provide a stable liposomal camp 
tothecin in therapeutically effective amounts, Wherein the 
drug is retained in the liposome under physiological condi 
tions for increased periods of time. This alloWs accumulation 
of the liposomal camptothecin formulations at a tumor site, 
With limited side effects on healthy cells and tissue, and 
further alloWs in situ delivery of the active lactone form of the 
drug to directly to tumor tissue in adequate concentrations for 
effective tumor cell killing and/ or groWth inhibition. 
By increasing intraliposomal pH and maintaining that pH 
prior to administration and during in vivo delivery to a tumor 
site, it has been surprisingly found that liposomal retention of 
a camptothecin may be prolonged, reducing the potential for 
exposure of healthy tissue to the drug When administered in 
vivo. This improvement in retention alloWs the drug to accu 
mulate at tumor tissue, i.e., an in vivo enhanced permeation 
and retention effect (Drummond et al., 1999). As the lipo 
somes accumulate Within the tumor tissue, over time the drug 
is released as the lactone form in situ, thus achieving release 
of drug in the active form directly at the tumor site, rather than 
drug residing in the bloodstream at physiological conditions 
favoring conversion to the inactive carboxylate form. Accord 
ingly, the problems of enhanced liposomal retention and 
delivery of the active lactone form camptothecin to a tumor 
site are simultaneously solved. 
The foregoing description of preferred embodiments has 
been presented for purposes of illustration and description. It 
is not intended to be exhaustive or limiting to the precise 
forms disclosed. Obvious modi?cations or variations are pos 
sible in light of the above teachings. The embodiments Were 
chosen and described to provide the best illustration of the 
principles described herein and their practical application to 
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thereby enable one of ordinary skill in the art to utilize the 
invention in various embodiments and With various modi? 
cations as are suited to the particular use contemplated. All 
such modi?cations and variations are Within the scope of the 
invention as determined by the appended claims When inter 
preted in accordance With the breadth to Which they are fairly, 
legally and equitably entitled. 
What is claimed is: 
1. A method for preparing a stable dispersion of a camp 
tothecin or analog thereof for delivery to a patient in need 
thereof, comprising: 
preparing a solution of a camptothecin, camptothecin pro 
drug, or analog thereof, said solution having a pH Which 
places substantially an entirety of that camptothecin or 
analog thereof in a carboxylate form; 
loading the solution of camptothecin, camptothecin pro 
drug, or analog thereof into a liposome comprised of at 
least one lipid, said liposome having an intraliposomal 
pH Which preserves substantially an entirety of said 
camptothecin, camptothecin prodrug, or analog thereof 
in the carboxylate form, said at least one lipid being 
selected to provide to said liposome a net neutral or 
anionic charge; and 
delivering said liposome loaded With said carboxylate form 
camptothecin, camptothecin prodrug, or analog thereof 
to a patient in need thereof, Whereby said liposome 
accumulates at a tumor site and said camptothecin, 
camptothecin prodrug, or analog thereof is released as 
an active, lactone form in situ at said tumor site. 
2. The method of claim 1, Wherein the solution of camp 
tothecin, camptothecin prodrug, or analog thereof is formu 
lated to have a pH of from about 8.0 to about 11.0. 
3. The method of claim 1, Wherein the lipid is selected from 
at least one of a phospholipid and a sterol. 
4. The method of claim 3, Wherein the phospholipid is 
selected from the group consisting of an egg phospholipid, a 
soy phospholipid, distearoylphosphatidyl choline, dipalmi 
toylphosphatidyl choline, diarachidonoyl phosphatidyl cho 
line, hydrogenated soy phosphatidyl choline, dimyris 
toylphosphatidyl glycerol, dioleylphosphatidylglycerol, 
dimyristoylphosphatidylcholine, phosphatidyl choline, phos 
phatidyl ethanolamine, and mixtures thereof. 
5. The method of claim 1, Wherein said liposome comprises 
a mixture of phospholipids including from about 5% to about 
10% of a pegylated phospholipid. 
6. The method of claim 4, Wherein said liposome comprises 
from about 70% to about 95% (W/v) of a ?rst phospholipid 
and from about 5% to about 10% (W/v) of a second, pegylated 
phospholipid. 
7. The method of claim 6, Wherein a chain length of the ?rst 
phospholipid is substantially the same as a chain length of the 
second, pegylated phospholipid. 
8. The method of claim 1, Wherein the camptothecin, 
camptothecin prodrug or analog thereof is selected from the 
group of neutral camptothecins, camptothecin prodrugs, and 
analogs consisting of camptothecin, DB-67, SN-38, gimate 
can, irinotecan, karenitecin, 9-nitro camptothecin, and mix 
tures thereof. 
9. A method for administering a stable solution of a neutral 
camptothecin, camptothecin prodrug, or analog thereof to a 
patient in need thereof, comprising: 
preparing a solution of a neutral camptothecin, camptoth 
ecin prodrug, or analog thereof, said solution having a 
pH Which places substantially an entirety of that neutral 
camptothecin, camptothecin prodrug, or analog thereof 
in substantially a carboxylate form; 
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loading the solution of neutral camptothecin, camptothecin 
prodrug, or analog thereof into a liposome comprised of 
at least one lipid, said liposome having an intraliposomal 
pH Which preserves substantially an entirety of said 
neutral camptothecin, camptothecin prodrug, or analog 
thereof in the carboxylate form, said at least one lipid 
being selected to provide to said liposome a net neutral 
or anionic charge; 
separating the liposome from any free neutral camptoth 
ecin, camptothecin prodrug, or analog thereof; and 
administering the liposome loaded With said carboxylate 
form neutral camptothecin, camptothecin prodrug, or 
analog thereof to a patient in need thereof Whereby the 
liposome accumulates at a tumor site and said neutral 
camptothecin, camptothecin prodrug, or analog thereof 
is released as an active, lactone form in situ at said tumor 
site. 
10. The method of claim 9, Wherein the solution of neutral 
camptothecin, camptothecin prodrug, or analog thereof is 
formulated to have a pH of from about 8.0 to about 11. 
11. The method of claim 9, Wherein the lipid is selected 
from at least one of a phospholipid and a sterol. 
12. The method of claim 11, Wherein the phospholipid is 
selected from the group consisting of an egg phospholipid, a 
soy phospholipid, distearoylphosphatidyl choline, dipalmi 
toylphosphatidyl choline, diarachidonoyl phosphatidyl cho 
line, hydrogenated soy phosphatidyl choline, dimyris 
toylphosphatidyl glycerol, dioleylphosphatidylglycerol, 
dimyristoylphosphatidylcholine, phosphatidyl choline, phos 
phatidyl ethanolamine, and mixtures thereof. 
13. The method of claim 9, Wherein said liposome com 
prises a mixture of phospholipids including from about 5% to 
about 10% of a pegylated phospholipid. 
14. The method of claim 12, Wherein said liposome com 
prises from about 70% to about 95% (W/v) of a ?rst phospho 
lipid and from about 5% to about 10% (W/v) of a second, 
pegylated phospholipid. 
15. The method of claim 14, Wherein a chain length of the 
?rst phospholipid is substantially the same as a chain length 
of the second, pegylated phospholipid. 
16. The method of claim 9, Wherein the neutral camptoth 
ecin, camptothecin prodrug, or analog thereof is selected 
from the group consisting of camptothecin, DB-67, SN-38, 
gimatecan, karenitecin, irinotecan, 9-nitro camptothecin, and 
mixtures thereof. 
17. A composition comprising a therapeutically suf?cient 
amount of a camptothecin, camptothecin prodrug, or analog 
thereof for the treatment of a cancer in an animal in need 
thereof, said camptothecin, camptothecin prodrug, or analog 
thereof being loaded into a liposome having an intraliposo 
mal pH suf?cient to maintain substantially an entirety of the 
intraliposomal camptothecin, camptothecin prodrug, or ana 
log thereof in a carboxylate form for delivery to said animal, 
Wherein said liposome is comprised of lipids Whereby said 
liposome has a net neutral or anionic charge. 
18. The composition of claim 17, Wherein the intraliposo 
mal pH is from about 8.0 to about 11.0. 
19. The composition of claim 7, Wherein the liposome 
comprises at least one of a phospholipid and a sterol. 
20. The composition of claim 19, Wherein the phospholipid 
is selected from the group consisting of an egg phospholipid, 
a soy phospholipid, distearoylphosphatidyl choline, dipalmi 
toylphosphatidyi choline, diarachidonoyl phosphatidyl cho 
line, hydrogenated soy phosphatidyl choline, dimyris 
toylphosphatidyi glycerol, dioleylphosphatidylglycerol, 
dimyristoylphosphatidylcholine, phosphatidyl choline, phos 
phatidyl ethanolamine, and mixtures thereof. 
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21. The composition of claim 19, wherein the liposome 
comprises a mixture of phospholipids including from about 
5% to about 10% of a pegylated phospholipid. 
22. The composition of claim 21, Wherein the liposome 
comprises from about 70% to about 95% (W/V) of a ?rst 
phospholipid and from about 5% to about 10% (W/V) of a 
second, pegylated phospholipid. 
23. The composition of claim 22, Wherein a chain length of 
the ?rst phospholipid is substantially the same as a chain 
length of the second, pegylated phospholipid. 
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24. The composition of claim 17, Wherein the camptoth 
ecin, camptothecin prodrug, or analog thereof is selected 
from the group of neutral camptothecins, camptothecin pro 
drugs, and analogs consisting of camptothecin, DB-67, 
SN-38, gimatecan, karenitecin, irinotecan, 9-nitro camptoth 
ecin, and mixtures thereof. 
